Latest The New England Journal Stories
Patients who are started on antiretroviral therapy for HIV-1 infection within four months of estimated infection date — and who have higher counts of CD4+ T-cells at the initiation of therapy — demonstrate a stronger recovery of CD4+ T-cell counts than patients in whom therapy is started later.
Older patients undergoing cardiac surgery often experience changes in cognitive function, such as memory problems or an inability to focus, in the days immediately following their operations.
A multicenter study involving a UT Southwestern Medical Center urogynecologist will eliminate some of the guesswork physicians face about whether to use a sling during vaginal prolapse repair to prevent urinary incontinence.
A new analysis of popular bone-building drugs by the US Food and Drug Administration (FDA) could prompt millions of women to rethink their use of such drugs, even though the agency fell short of issuing specific recommendations.
A new topical gel now available by prescription significantly decreases the amount of time needed to treat actinic keratosis, a skin condition that is a common precursor to skin cancer.
The cost of medications through Medicare's subsidized prescription drug program varies from region to region across the United States largely due to the use of more expensive brand-name drugs and not because of the amount of drugs prescribed.
LigoCyte Pharmaceuticals, Inc. announced today that its experimental vaccine provided significant protection against norovirus infection and related gastrointestinal illness collectively known as acute gastroenteritis (AGE).
Over time, epileptic seizures can lead to major health issues, including significant cognitive decline and even death, warns Orrin Devinsky, MD, professor, Departments of Neurology, Neurosurgeryand Psychiatryat NYU Langone Medical Center.
A new oral drug has been shown in a large international clinical trial to significantly reduce the relapse rate of people with multiple sclerosis and to slow the progression of the disease.
A new multinational study finds that a 24-week treatment course for hepatitis C that adds telaprevir to peginterferon alfa and ribavirin is just as effective as a 48-week regimen for many patients.